CHICAGO — Altris AI has introduced a new update to its technology that automatically flags OCT scans for popular biomarkers and pathologies of disease.
With Altris AI’s new functionality, ECPs can instantly identify OCT scans with specific retina pathologies or biomarkers from the list of over 70 conditions. For example, clinicians can locate OCT scans of all patients with a Soft Drusen or Dry AMD, forming cohorts for clinical or research purposes.
How it works
The flagging system is precise and enables fast, targeted searches across historical records and large datasets—including OCT scans from different devices. This advancement supports a more efficient workflow and enhances access to critical data for both diagnostics and research.
“Flags are a clinical shortcut. Instead of manually searching through thousands of scans, you can now filter precisely for what you need—whether that’s subretinal fluid, GA progression or early glaucoma indicators. It’s about making the data work for you,” said Maria Znamenska, MD, PhD, Chief Medical Officer at Altris AI.
What it does for ECPs
With flags for smart filtering, eye care specialists can:
- Track risk-related biomarkers and set reminders for patient follow-ups.
- Quickly identify eligible candidates for clinical studies by searching through large volumes of data.
- Confidently introduce new treatments by finding the right patient profiles.
- Filter rare or complex cases to study unique combinations of pathologies and biomarkers and their progression.
“Flags make it possible to build patient cohorts in minutes,” Dr. Znamenska said. “Whether it’s for the research or for introducing the new therapy, you now have a reliable tool to search for the right patients efficiently.
The release of flags reinforces Altris AI’s position as a leading AI decision support platform for OCT analysis for both clinical care and research purposes. By enabling customizable filtering across over 70 pathologies and biomarkers, flags support better disease tracking, faster research, and more personalized treatment planning.
Author
